Physician profile
Ryan C Young
NPI 1902127947
$105,359.53
in general payments reported to CMS, 2019-2025
23 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $275 · 2021: $454 · 2022: $47K · 2023: $55K · 2024: $477 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,660.00 |
| Food and Beverage | $1,506.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $101,595.00 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| Regeneron Healthcare Solutions, INC. | $524.49 | 2019-2025 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $381.42 | 2019-2021 | |
| Abbvie INC. | $377.03 | 2019-2025 | Vuity, Alphagan P, Lumigan |
| Genentech USA, INC. | $356.23 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $279.84 | 2023-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $274.81 | 2019 | |
| Biotissue Holdings INC. | $204.85 | 2019-2020 | |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Carl Zeiss Meditec, INC. | $175.63 | 2020 | |
| Welch Allyn | $150.00 | 2019 | |
| Allergan, INC. | $128.22 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $125.00 | 2024 | |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Kala Pharmaceuticals, INC. | $102.76 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $100.00 | 2019 | |
| Astellas Pharma US INC | $98.60 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $47.56 | 2025 | Triesence |
| Biogen, INC. | $45.36 | 2023-2024 | Byooviz |
| Mallinckrodt Hospital Products INC. | $42.75 | 2022-2025 | Acthar |
| Alimera Sciences, INC. | $24.48 | 2024 | Yutiq, Iluvien |
| Ani Pharmaceuticals, INC. | $21.92 | 2025 | Yutiq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.